Bioxel Pharma

Bioxel Pharma was a Canadian biopharmaceutical company focused on the development and manufacturing of taxane-based oncology treatments. The company utilized proprietary technology for the extraction and purification of naturally derived compounds to produce high-quality active pharmaceutical ingredients (APIs) such as paclitaxel and docetaxel. Its clinical pipeline featured BXL628, a specialized formulation of paclitaxel designed for intravesical administration in patients with bladder cancer. In 2010, the company was acquired by Sagent Pharmaceuticals, integrating its taxane expertise into Sagent's broader injectable drug portfolio.